TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Mind-body Awareness Training and Brain-computer Interface

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Apparently healthy volunteers~* Age 18-64, inclusive.~* Willing and able to provide written consent.~* Able to communicate in the English language.~Exclusion Criteria:~* Any past BCI experience.~* Pregnancy~* Any breathing, movement, or visual disorders.~* Any active neurological or mental disorders.~* History of epilepsy.~* History of a vascular or cardiac disorder (e.g. heart disease)~* History of a metabolic disorder (e.g. diabetes)~* Any other condition which would make the subject, in the opinion of the investigator, unsuitable for the study.~Exclusion criteria that would prevent subjects from participating in the optional MRI component will be:~* Any MRI incompatible indwelling metal objects or implantable devices, including but not limited to the following (dental mental is allowable):~  * Cardiac pacemaker~ * Implanted cardiac defibrillator~ * Carotid artery vascular clamp~ * Intravascular stents, filters, or coils~ * Aortic clip~ * Internal pacing wires~ * Vascular access port and/or catheter~ * Swan-Ganz catheter~ * Shunt (spinal or intraventricular)~ * Aneurysm clip(s)~ * Neurostimulator~ * Electrodes (on body, head, or brain)~ * Heart valve prosthesis~ * Any type of prosthesis (eye, penile, etc.)~ * Artificial limb or joint replacement~ * Bone growth/fusion stimulator~ * Bone/joint pin, screw, nail, wire, plate~ * Metal rods in bones~ * Harrington rods (spine)~ * Metal or wire mesh implants~ * Wire sutures or surgical staples~ * Insulin pump or infusion device~ * Any metal fragments (i.e. metal shop)~ * Any implant held in place by a magnet~ * Cochlear, otologic, or ear implant~* Claustrophobia~* Hearing aid use~* Any yoga/meditation in the last three months.~* More than 12 yoga/meditation classes in the last 12 months.~* Approximately weekly yoga/meditation for a year or more at any point in the past.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Mindfulness Based Stress Reduction (Type: EXPERIMENTAL): Participants will attend an 8-week Mindfulness Based Stress Reduction (MBSR) course between pre- and post-testing.
- Waitlist (Type: NO_INTERVENTION): Participants will be added to a waitlist intervention group for 8-weeks between pre-and post-testing.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine if Caffeine Accelerates Emergence From Anesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 25-40.~2. Male.~3. Normal healthy subject without systematic diseases or conditions.~4. Metabolic Equivalents of Functional Capacity \>= 5.~5. Low risk for Obstructive Sleep Apnea (OSA) based on the screening test (STOP-bang score established by American Society of Sleep Apnea): Yes to \> 3 items- high risk of OSA~6. No History of Arrhythmia (Baseline EKG will be obtained during the history and physical session), seizure, liver and kidney diseases.~7. BMI \< 30 kg/m2.~8. No history of prior difficulty with anesthesia.~9. No personal or family history of malignant hyperthermia.~10. No history of any mental illness.~11. No history of drugs or alcohol abuse (urine drug screens required).~12. Subjects capable of giving consent.~13. Living less than 30 miles away from University of Chicago.~14. No history of seizure disorders.~15. No history of head trauma.~Exclusion Criteria:~1. Age \<25 or \>40.~2. Female.~3. ASA physical status \> 1 (normal healthy subject without systematic diseases or conditions)~4. Metabolic Equivalents of Functional Capacity (METs) \< 5.~5. High risks for Obstructive Sleep Apnea (OSA) based on the screening test (STOP-bang score established by American Society of Sleep Apnea): Yes to \> 3 items- high risk of OSA~6. History Arrhythmia (Baseline EKG will be obtained during the history and physical session), seizure, liver and kidney diseases~7. BMI\>30 kg/m2.~8. Prior difficulty with anesthesia.~9. Personal or family history of malignant hyperthermia.~10. History of any mental illness.~11. History of drugs or alcohol abuse (urine drug screens required)~12. Subjects capable of giving consent~13. Living more than 30 miles away from University of Chicago.~14. History of seizure disorders.~15. History of head trauma.

- Gender: MALE
- Minimum Age: 25 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Anesthetized volunteers will be allowed to wake after injection of either saline (placebo control) or caffeine (15 mg/ kg). The time to wake will be measured.
- Caffeine (Type: ACTIVE_COMPARATOR): Anesthetized volunteers will be allowed to wake after injection of either saline (placebo control) or caffeine (15 mg/ kg). The time to wake will be measured.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Liver tumor diagnosed histologically as HCC or suspected of being HCC in association with serum alpha-fetoprotein level \> 200 or tumor mass with characteristics of malignancy on diagnostic imaging~* Under the care of a surgical attending~* Deemed a surgical candidate and has agreed to surgery to remove a portion of the liver containing tumor~* Child-Pugh A/B~Exclusion Criteria:~* Weight \> 350 lbs~* Pregnant or lactating female, a serum pregnancy test will be performed within 2 weeks or less before the date of the FCH PET/CT scan in all women capable of becoming pregnant~* Serious underlying medical condition that would impair patient's ability to tolerate the imaging procedure~* Concurrent treatment with chemotherapy, molecule-selective, biological, or radiotherapeutic agent

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 18F-fluoromethylcholine PET/CT (Type: EXPERIMENTAL): Patients undergo 18F-fluoromethylcholine positron emission tomography (PET)/ computed tomography (CT) scan within 14 days of surgical resection of liver tumor.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy in Treating Young Patients With Langerhans Cell Histiocytosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histopathologically confirmed diagnosis of Langerhans cell histiocytosis according to the criteria defined by the Histiocyte Society~  * Demonstration of CD1a antigenic determinants on the surface of lesional cells (by immunocytology or immunohistology) or Birbeck granules in lesional cells by electron microscopy~* Considered at risk or low risk according to the following criteria:~  * Multi-system at risk disease, defined as involvement of one or more risk organs (i.e., hematopoietic system, liver, spleen, or lungs)~    * No single-system lung involvement~ * Multi-system low-risk disease~    * Multiple organs involved but without involvement of risk organs~ * Single-system disease~    * Multifocal bone disease (i.e., lesions in 2 or more different bones)~   * Localized special site involvement, such as CNS-risk lesions with intracranial soft tissue extension or vertebral lesions with intraspinal soft tissue extension~      * Vault lesions are not regarded as CNS-risk lesions~PATIENT CHARACTERISTICS:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~* No prior treatment for Langerhans cell histiocytosis

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Menstrual Blood Stem Cells in Poor Ovarian Responders

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Serum AMH \< 0.1 ng/ml (at the screening visit and in the absence of OC or sex-steroid intake)~* Antral follicular count (AFC) in both ovaries \< 4 (at screening visit and in the absence of OC or sex-steroid intake)~* Positive history of at least1 standard previous IVF-ET or ICSI-ET~* Normal thyroid hormones (TSH and FT4)~* Normal level of prolactin,~* Normal level of fasting blood sugar~* Normal Liver tests (SGOT, SGPT)~* Normal level of BUN, creatinine~* Negative Infectious tests (HIV, HCV, HBS Ag, VDRL)~* Normal coagulation factors (PT, PTT, BT, CT)~* Normal serum levels of sodium, potassium, calcium, phosphorus~* Negative history of endometrioma or other ovarian cysts~* Negative history of previous ovarian surgery~* Negative history of cancer~* Negative history of a known autoimmune disorder.~Exclusion Criteria:~* Positive history of hydrosalpinx or anatomical uterine disorders (In vaginal sonography or HSG)~* Severe male factors of their husbands (count \<15 million/ml)

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- MenSCs group (Type: EXPERIMENTAL): Study group, treated with autologous intra-ovarian MenSCs injection and monitored for spontaneous pregnancy for 3 months after intervention. ICSI was used in cases where the pregnancy did not occur naturally.
- ICSI group (Type: NO_INTERVENTION): Control group, monitored for spontaneous pregnancy for 3 months after their last ovarian stimulation for ICSI or IVF. ICSI was used in cases where the pregnancy did not occur naturally.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extended Analysis for Leukemia/Lymphoma Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. There are no further standard treatments available for the patient;~2. The patient has undergone at least two lines of previous therapy;~3. Cancer cell-containing biopsies are obtainable;~4. Informed consent from the patient was given;~5. candidate treatments identified by ngFDS are clinically available and considered safe given the patient health state.~Exclusion Criteria:~1. Presence of further treatment options, as defined by NCCN guidelines or Austrian guidelines representing a possible further treatment-related response by conventional therapies according to generally accepted medical evidence.~2. No fresh and viable tumor material available.~3. Unresolved toxicity of National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (NCI CTCAE v4.0) Grade 2 or higher from previous anti-cancer therapy, except alopecia.~4. Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption of drugs.~5. A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection.~6. A history of known glucose-6-phosphate dehydrogenase (G6PD) deficiency.~7. History of other malignancy. Subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.~8. Uncontrolled medical conditions (i.e, diabetes mellitus, hypertension, etc), psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol; or unwillingness or inability to follow the procedures required in the protocol.~9. Pregnant or lactating females.~10. History of alcohol or drug abuse within 6 months prior to screening.~11. No informed consent available.~12. Exclusion criteria effective for respective treatment agents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ngFDS selected treatment (Type: None): Treatment with commercially available treatments (per package insert instructions) chosen via next-generation functional drug screening (ngFDS).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject must have a histologically confirmed NKTL at study site.~2. Subject must have relapsed or refractory NKTL after prior asparaginase-based chemotherapy or chemo radiotherapy.~3. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.~4. Subject must have at least one evaluable or measurable lesion per Lugano 2014 classification.~5. Subject must have adequate organ function and bone marrow function without severe hematopoietic disorder, or heart, lung, liver or kidney dysfunction or immune deficiency.~6. Subject must provide stained tumor tissue sections and corresponding pathological report or unstained tumor tissue sections (or tissue block) for central pathology review.~7. Subject with prior anti-cancer treatment can only be enrolled when the toxicity of prior anti-cancer treatment has recovered to baseline or ≤ Grade 1 according to Common Terminology Criteria for Adverse Events (CTCAE) v4.03.~Exclusion Criteria:~1. Invasive natural killer leukemia.~2. Concomitant with hemophagocytic syndrome.~3. Primary site in central nervous system (CNS) or CNS involvement.~4. Subjects currently participating in other clinical studies or use of any investigational drug within 4 weeks prior to the first dose of CS1001.~5. Subjects who received systemic corticosteroid or any other immunosuppressive therapy within 14 days prior to the first dose of CS1001.~6. Subjects who had prior chemotherapy, immune therapy, biological therapy as systemic treatment for cancer, within 28 days prior to the first dose of CS1001.~7. Receipt of traditional medicinal herbal preparations with anti-tumor indications with 7 days prior to the first dose of CS1001.~8. Known history of human immunodeficiency virus (HIV) infection and/or acquired immune deficiency syndrome.~9. Subjects with active hepatitis B or C infection.~10. Subjects with active tuberculosis infection.~11. Subjects who received prior therapy with anti-PD-1, anti-PD-L1 or anti-CTLA-4 monoclonal antibody.~12. Female subjects who are pregnant or breast-feeding.~For more information regarding trial participation, please contact at cstonera@cstonepharma.com

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CS1001 (Type: EXPERIMENTAL): Participants will receive CS1001 1200 mg by intravenous infusion every 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Inspiratory Muscle Training in Patients With Bronchiectasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Bronchiectasis confirmed by clinical history, pulmonary function test, and high resolution computed tomography~Exclusion Criteria:~* Had recent exacerbation within six weeks~* Use of corticosteroid~* With poor consciousness level~* Have cerebro-vascular or neuro-muscular disorders

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: NO_INTERVENTION): No intervention.
- Inspiratory muscle training (Type: EXPERIMENTAL): With intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chemoembolization for Lung Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Lung, endobronchial, pleural, or mediastinal metastases that are not responding to systemic chemotherapy, and that are not amenable to ablation, resection, or SBRT.~* At least 18 years old.~* ECOG performance status 0 or 1~Exclusion Criteria:~* Primary lung cancer~* \>50% of a lung is replaced with tumor~* Oxygen saturation \<92% on room air~* FEV1 \<60%~* Pulmonary hypertension (diagnosed or suspected on echocardiography, CT, MRI, or direct pressure measurement)~* Recent pulmonary embolism (within 3 months)~* Pulmonary arteriovenous malformation~* Active lung infection (pneumonia, empyema, or lung abscess requiring therapy within 1 month)~* Symptomatic heart failure (dyspnea, volume overload)~* Left bundle branch block (contraindication to pulmonary angiography)~* Renal failure (eGFR \<30 mL/min/1.73m\^2)~* Pregnancy~* Breastfeeding~* Altered mental status that would interfere with consent or follow-up~* Platelets \< 100,000 (after transfusion, if needed)~* INR\>2 (after transfusion, if needed)~* Hemoglobin \<7 (after transfusion, if needed)~* Hyperthyroidism (contraindication to lipiodol)~* Planned radioactive iodine imaging or therapy (contraindication to lipiodol)~* Allergy to lipiodol or mitomycin~* Allergy to iodinated contrast that can not be treated with steroid / diphenhydramine premedication~* Any condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product or interpretation of subject safety or study results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lung, Endobronchial, Mediastinal or Pleural Metastases (Type: EXPERIMENTAL): Participants will have unresectable and unablatable lung, endobronchial, mediastinal, or pleural metastases (from any primary) that are not responding to chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Total Hip Arthroplasty (THA) Lumbar Plexus Verses Periarticular

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients with an American Society of Anesthesiologists (ASA) physiological status I-III~2. Patients presenting for unilateral primary total hip arthroplasty~3. Patients 18 years of age and older~Exclusion Criteria:~1. Chronic pain syndromes such as fibromyalgia or complex regional pain syndrome~2. History of long term use of daily opioids (\>1 months) with Oral Morphine Equivalent (OME) \>5mg/day~3. Body mass index (BMI) \> 40 kg/m2~4. Allergies to medications used in this study such as: fentanyl,hydromorphone, ketorolac, ibuprofen, acetaminophen, local anesthetics, oxycodone, tramadol, ondansetron, droperidol, dexamethasone, celecoxib and OxyContin~5. Major systemic medical problems such as:~   1. severe renal disorder defined as glomerular filtration rate (GFR) \<50 units/m2~  2. cardiovascular disorders defined as Congestive Heart Failure (CHF) New York Heart Association (NYHA) class III-IV~  3. severe hepatic disorder defined as current or past diagnosis of acute/subacute necrosis of liver, acute hepatic failure, chronic liver disease, cirrhosis (primary biliary cirrhosis), fatty liver, chronic hepatitis/toxic hepatitis, liver abscess, hepatic coma, hepatorenal syndrome, other disorders of liver~6. Impaired cognitive function or inability to understand the study protocol~7. Contraindication to a regional anesthesia technique (e.g., preexisting neuropathy in the operative extremity, coagulopathy \[platelets \< 100,000, International Normalized Ratio (INR) \>1.5\], refusal, etc.).~8. Previous contralateral hip replacement managed with regional or periarticular injection~9. Unable to follow-up at the 3 month interval at Mayo Clinic in Rochester, Minnesota~10. Pregnancy or breastfeeding (women of child-bearing potential will require a negative pregnancy test)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- PNB Bupivacaine (Type: ACTIVE_COMPARATOR): Bupivacaine 0.5% with 1:200,000 epinephrine 30 ml bolus preoperatively followed by an infusion of bupivacaine 0.2% on post anesthesia care unit (PACU) arrival.
- PAI Ropivacaine (Type: ACTIVE_COMPARATOR): Patients 50 to 74.9 kg: ropivacaine 200 mg, epinephrine 100 ug, ketorolac 30 mg. Patients 75 to 99.9 kg: ropivacaine 300 mg, epinephrine 200 ug, ketorolac 30 mg. Patients 100 to 125 kg: ropivacaine 400 mg, epinephrine 300 ug, ketorolac 30mg.
- PAI liposomal bupivacaine (Type: ACTIVE_COMPARATOR): Liposomal bupivacaine 255 mg, ketorolac 30 mg, bupivacaine 125 mg, epinephrine 125 ug.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete